Amneal to Report Fourth Quarter and Full Year 2018 Results on February 28, 2019

BRIDGEWATER, N.J., Jan. 24, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on February 28, 2019. 

The financial results and live webcast will be accessible through the Investor Relations section of the Company's Web site at https://investors.amneal.com.

To access the call through a conference line, dial (866) 652-5200 (in the U.S.) and (412) 317-6060 (international callers).

A replay of the conference call will be available for seven days shortly after the call. To access the replay, dial (877) 344-7529 (in the U.S.) and (412) 317-0088 (international callers). The access code for the replay is 10128077.

The Company also announced that it expects to report 2019 quarterly financial results on the following dates prior to the open of the U.S. financial markets and will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time.

About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is an integrated pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has approximately 6,000 employees in its operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal is one of the largest generic pharmaceutical manufacturers in the United States, with an expanding portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty Pharma division focused principally on central nervous system disorders, endocrinology and parasitic infections. For more information, visit www.amneal.com.

Contact:                                                                 
Mark Donohue
Investor Relations and Corporate Communications 
(908) 409-6718                                                       
www.amneal.com                                                   

SOURCE Amneal Pharmaceuticals, Inc.

Related Links

http://www.amneal.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED